Epidemiology of Pyrazinamide-Resistant Tuberculosis in the United States, 1999–2009
Open Access
- 9 July 2013
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 57 (8), 1081-1093
- https://doi.org/10.1093/cid/cit452
Abstract
Background. Pyrazinamide (PZA) is essential in tuberculosis treatment. We describe the prevalence, trends, and predictors of PZA resistance in Mycobacterium tuberculosis complex (MTBC) in the United States. Methods. We analyzed culture-positive MTBC cases with reported drug susceptibility tests for PZA in 38 jurisdictions routinely testing for PZA susceptibility from 1999 to 2009. National Tuberculosis Genotyping Service data for 2004–2009 were used to distinguish M. tuberculosis from Mycobacterium bovis and determine phylogenetic lineage. Results. Overall 2.7% (2167/79 321) of MTBC cases had PZA resistance, increasing annually from 2.0% to 3.3% during 1999–2009 (P < .001), largely because of an increase in PZA monoresistance. PZA-monoresistant MTBC (vs drug-susceptible) was associated with an age of 0–24 years (adjusted prevalence ratio [aPR],1.50; 95% confidence interval [CI], 1.31–1.71), Hispanic ethnicity (aPR, 3.52; 95% CI, 2.96–4.18), human immunodeficiency virus infection (aPR, 1.43; 95% CI, 1.15–1.77), extrapulmonary disease (aPR, 3.02; 95% CI, 2.60–3.52), and normal chest radiograph (aPR, 1.88; 95% CI, 1.63–2.16) and was inversely associated with Asian (aPR, 0.59; 95% CI, .47–.73) and black (aPR, 0.37; 95% CI, .29–.49) race. Among multidrug-resistant (MDR) cases, 38.0% were PZA-resistant; PZA resistance in MDR MTBC was associated with female sex (aPR, 1.25; 95% CI, 1.08–1.46) and previous tuberculosis diagnosis (aPR, 1.37; 95% CI, 1.16–1.62). Of 28 080 cases with genotyping data, 925 (3.3%) had PZA resistance; 465 of 925 (50.3%) were M. bovis. In non-MDR M. tuberculosis cases, PZA resistance was higher in the Indo-Oceanic than the East Asian lineage (2.2% vs 0.9%, respectively; aPR, 2.26; 95% CI, 1.53–3.36), but in MDR cases it was lower in the Indo-Oceanic lineage (22.0% vs 43.4%, respectively; aPR, 0.54; 95% CI, .32–.90). Conclusions. Specific human and mycobacterial characteristics were associated with PZA-resistant MTBC, reflecting both specific subgroups of the population and phylogenetic lineages of the mycobacteria.Keywords
This publication has 34 references indexed in Scilit:
- Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Performance of Tuberculosis Drug Susceptibility Testing in U.S. Laboratories from 1994 to 2008Journal of Clinical Microbiology, 2012
- Validation of pncA Gene Sequencing in Combination with the Mycobacterial Growth Indicator Tube Method To Test Susceptibility of Mycobacterium tuberculosis to PyrazinamideJournal of Clinical Microbiology, 2012
- Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2011
- Characteristics of pncA mutations in multidrug-resistant tuberculosis in TaiwanBMC Infectious Diseases, 2011
- Molecular Detection of Mutations Associated with First- and Second-Line Drug Resistance Compared with Conventional Drug Susceptibility Testing of Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2011
- Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, ThailandBMC Microbiology, 2010
- Potential for Erroneous Results Indicating Resistance When Using the Bactec MGIT 960 System for Testing Susceptibility of Mycobacterium tuberculosis to PyrazinamideJournal of Clinical Microbiology, 2010
- Pyrazinamide Resistance among South African Multidrug-Resistant Mycobacterium tuberculosis IsolatesJournal of Clinical Microbiology, 2008
- Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong KongJournal of Antimicrobial Chemotherapy, 2007